SYROS PHARMACEUTICALS INC's ticker is and the CUSIP is 87184Q206. A total of 60 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,217,963 | -3.6% | 1,786,427 | 0.0% | 1.93% | +30.4% |
| Q1 2024 | $9,557,384 | -31.3% | 1,786,427 | 0.0% | 1.48% | -31.7% |
| Q4 2023 | $13,916,266 | +299.7% | 1,786,427 | +102.7% | 2.16% | +103.1% |
| Q3 2023 | $3,481,728 | +25.4% | 881,450 | 0.0% | 1.07% | +118.9% |
| Q2 2023 | $2,776,568 | +18.0% | 881,450 | 0.0% | 0.49% | +0.2% |
| Q1 2023 | $2,353,472 | -25.6% | 881,450 | 0.0% | 0.49% | -28.6% |
| Q4 2022 | $3,164,406 | – | 881,450 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,786,427 | $9,217,963 | 1.93% |
| Bain Capital Life Sciences Investors, LLC | 2,749,808 | $14,189,009 | 1.56% |
| Opaleye Management Inc. | 865,443 | $4,465,686 | 1.02% |
| Omega Fund Management, LLC | 251,270 | $1,296,553 | 0.96% |
| Flagship Pioneering Inc. | 1,293,849 | $6,676,261 | 0.79% |
| Exome Asset Management LLC | 159,175 | $821,344 | 0.72% |
| Blue Owl Capital Holdings LP | 340,855 | $1,758,812 | 0.49% |
| Avidity Partners Management LP | 1,673,538 | $8,635,456 | 0.37% |
| Artal Group S.A. | 2,505,013 | $12,925,867 | 0.33% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 37,789 | $194,991 | 0.25% |